Literature DB >> 15289861

Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis.

Koichi Ohshima1, Kennosuke Karube, Riko Kawano, Takeshi Tsuchiya, Hiroaki Suefuji, Takahiro Yamaguchi, Junji Suzumiya, Masahiro Kikuchii.   

Abstract

WHO classification for malignant lymphoma was recently proposed. However, PTCL is heterogeneous. Chemokines and its receptors are closely associated with the T-cell subtypes. To clarify the T-cell subtype in PTCL, we conducted DNA chips of chemokine, its receptor (R) and cytokines. Angioimmunoblastic T-cell lymphoma (AILD, n=4), anaplastic large cell lymphoma (ALCL, n=4), adult T-cell leukemia lymphoma (ATLL, n=7), NK-cell lymphoma (NKL, n=2) and PTCL, unspecified (PTCL-U, n=6) were analyzed using DNA chips. In addition, immunological stainings were performed in 280 cases. In DNA chip, AILD, ALCL, NKL and ATLL showed a tendency for respective clusters, otherwise, PTCL-U clustered with AILD, ALCL and ATLL. From the gene expression profiling, CCR4, CCR3, MIG, CXCR3 and BLC were selected for immunohistochemistry. ATLL (n=48) expressed CCR4. ALCL (n=26) expressed CCR3, NKL (n=20) expressed MIG, and AILD (n=29) expressed CXCR3 and/or BLC. From the expression patterns, PTCL-U (n=134) were classified into three groups; CCR4 type (CCR4(+), n=42), CCR3 type (CCR3(+), n=31) and CXCR3 type (CXCR3(+) BLC(+/-), n=54). The prognosis was poor for ATLL, intermediate for AILD and favorable for ALCL (P=0.0014). Among PTCL-U, CCR4 type, CXCR3 type and CCR3 type had prognoses equivalent to ATLL, AILD and ALCL, respectively (P<0.0001).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289861

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?

Authors:  Karen L Grogg; Ayoma D Attygalle; William R Macon; Ellen D Remstein; Paul J Kurtin; Ahmet Dogan
Journal:  Blood       Date:  2005-08-15       Impact factor: 22.113

2.  Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.

Authors:  Naoko Asano; Ritsuro Suzuki; Koichi Ohshima; Yoshitoyo Kagami; Fumihiro Ishida; Tadashi Yoshino; Hiroshi Ogawa; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

3.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Lauren C Pinter-Brown; Francine M Foss; Lubomir Sokol; Jeffrey L Jorgensen; Pramoda Challagundla; Karen M Dwyer; Xiaoping Zhang; Michael R Kurman; Rocco Ballerini; Li Liu; Youn H Kim
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

Review 4.  Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential.

Authors:  Madeleine Duvic; Mark Evans; Casey Wang
Journal:  Ther Adv Hematol       Date:  2016-03-17

Review 5.  New molecular insights into peripheral T cell lymphomas.

Authors:  Stefano A Pileri; Pier Paolo Piccaluga
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

6.  Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma.

Authors:  Shih-Sung Chuang; Ryo Ichinohasama; Jan-Show Chu; Koichi Ohshima
Journal:  Int J Hematol       Date:  2010-03-04       Impact factor: 2.490

7.  Antibody therapy for Adult T-cell leukemia-lymphoma.

Authors:  Takashi Ishida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

8.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

Authors:  Javeed Iqbal; Dennis D Weisenburger; Timothy C Greiner; Julie M Vose; Timothy McKeithan; Can Kucuk; Huimin Geng; Karen Deffenbacher; Lynette Smith; Karen Dybkaer; Shigeo Nakamura; Masao Seto; Jan Delabie; Francoise Berger; Florence Loong; Wing Y Au; Young-Hyeh Ko; Ivy Sng; James Olen Armitage; Wing C Chan
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

9.  Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy.

Authors:  H Ryan Kolb; Nicholas Borcherding; Weizhou Zhang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

10.  Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report.

Authors:  Yukie Fujita; Aya Nakaya; Shinya Fujita; Masaaki Hotta; Hideaki Yoshimura; Yoshiko Azuma; Takahisa Nakanishi; Atsushi Satake; Kazuyoshi Ishii; Tomoki Ito; Shosaku Nomura
Journal:  Mol Clin Oncol       Date:  2015-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.